2869147-44-2
Chemical Structure
Enicepatide
Synonym(s): CT-388
- CAS No.: 2869147-44-2
- Formula:C226H345FN48O67
- Molecular Weight:4825.44
SMILES: O=C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(NC(C)(C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)C(N[C@@H](C)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC4=CNC5=CC=CC=C45)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(NCC(NCC(N6[C@@H](CCC6)C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N7[C@@H](CCC7)C(N8[C@@H](CCC8)C(N9[C@@H](CCC9)C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCNC(C(C)(C%10=CC(F)=CC(C#N)=C%10)C)=O
Biological Activity: Enicepatide (CT-388) is a cAMP signal-biased dual GLP-1R and GIPR agonist peptide, with an EC50 value of 0.087 nM for GLP-1R cAMP, and an EC50 value of 2.47 nM for GIPR cAMP. Enicepatide activates the cAMP signaling pathway, while recruiting only minimal amounts of β-arrestin-2 at both targets and reducing receptor internalization levels. Enicepatide improves glycemic control, reduces body weight, suppresses appetite, and ameliorates the pathological conditions of metabolic dysfunction-associated steatohepatitis. Enicepatide can be used in the research of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Enicepatide | 98.16% | Enicepatide (CT-388) is a cAMP signal-biased dual GLP-1R and GIPR agonist peptide, with an EC50 value of 0.087 nM for GLP-1R cAMP, and an EC50 value of 2.47 nM for GIPR cAMP. Enicepatide activates the cAMP signaling pathway, while recruiting only minimal amounts of β-arrestin-2 at both targets and reducing receptor internalization levels. Enicepatide improves glycemic control, reduces body weight, suppresses appetite, and ameliorates the pathological conditions of metabolic dysfunction-associated steatohepatitis. Enicepatide can be used in the research of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chakravarthy MV, et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity. Molecular metabolism. 2026 Jan;103:102291. [Content Brief]
- [2]. Neumann J, et al. Future GLP-1 receptor co-agonists and their cardiac effects[J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2026: 1-15.
